Home › Funds › Saturn V Capital Management LP › AMLX

Saturn V Capital Management LP position in AMLX

AMYLYX PHARMACEUTICALS INC · Health Care

Saturn V Capital Management LP reported holding 4,471,356 shares of AMLX (AMYLYX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$130.1M, representing 19.05% of its reported portfolio and ranking #1 among its reported holdings. Saturn V Capital Management LP has disclosed AMLX holdings in 10 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)4.47M sh
Reported value held$130.12M
Portfolio Weight19.05%
First reportedQ3 2023
Last changeReduce
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How Saturn V Capital Management LP's AMLX position evolved

Saturn V Capital Management LP first disclosed a stake in AMLX in Q3 2023 at 886,143 shares (US$16.2M). The position peaked in Q3 2026 at 4,471,356 shares, worth US$130.1M. Across 10 filings, Saturn V Capital Management LP increased the stake 5 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 4,471,356 shares valued at US$130.1M — a reduction of -152,745 shares quarter over quarter.. Notable position changes include a 173% increase in Q1 2025 (shares rose 81% over the following quarter), a 34% increase in Q2 2025 (shares rose 112% over the following quarter), a 41% increase in Q3 2025 (shares fell 11% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 886.14K $16.23M New
Q4 2023 1.10M $16.18M Add
Q4 2024 889.07K $3.36M New
Q1 2025 2.43M $8.59M Add
Q2 2025 3.26M $20.90M Add
Q3 2025 4.60M $62.58M Add
Q4 2025 4.50M $54.32M Reduce
Q1 2026 4.35M $60.46M Reduce
Q2 2026 4.62M $83.05M Add
Q3 2026 4.47M $130.12M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About AMLX and 13F data

AMLX (AMYLYX PHARMACEUTICALS INC) is a Health Care company. 46 other funds we track also report a position in AMLX — the largest reported positions include TCG Crossover Management, LLC (US$181.7M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$158.0M), PERCEPTIVE ADVISORS LLC (US$149.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding AMLX

All AMLX fund holders →

FAQ

How long has Saturn V Capital Management LP held AMLX?

Saturn V Capital Management LP has disclosed AMLX holdings in 10 of the last 13 reported quarters, going back to Q3 2023.

What is Saturn V Capital Management LP's current position in AMLX?

As of Q3 2026, Saturn V Capital Management LP holds 4.47M shares of AMLX (AMYLYX PHARMACEUTICALS INC), valued at $130.12M, representing 19.05% of its reported portfolio and ranking #1.

Has Saturn V Capital Management LP been buying or selling AMLX?

In the latest 13F filing (Q3 2026), Saturn V Capital Management LP reduced its position in AMLX. The position peaked in Q3 2026 at 4.47M shares.

Which other funds hold AMLX?

Other major institutional holders of AMLX include TCG Crossover Management, LLC, DRIEHAUS CAPITAL MANAGEMENT LLC, PERCEPTIVE ADVISORS LLC, among 46 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.